a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, tyrosine (receptor); Membrane protein, integral; EC 126.96.36.199; Protein kinase, TK; Kinase, protein; TK group; FGFR family
Cellular Component: internal side of plasma membrane; cell surface; membrane; perinuclear region of cytoplasm; lysosome; integral to plasma membrane; cytoplasm; integral to membrane; nucleus
Molecular Function: transferase activity; protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; nucleotide binding; transmembrane receptor protein tyrosine kinase activity; kinase activity; ATP binding
Biological Process: peptidyl-tyrosine phosphorylation; somatic stem cell maintenance; positive regulation of apoptosis; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; positive regulation of tyrosine phosphorylation of Stat3 protein; regulation of apoptosis; negative regulation of cell proliferation; substantia nigra development; cell-cell signaling; positive regulation of MAPKKK cascade; inner ear receptor cell differentiation; positive regulation of cell proliferation; forebrain development; morphogenesis of an epithelium; response to axon injury; cell differentiation; oligodendrocyte development; inner ear development; negative regulation of epithelial cell proliferation; fibroblast growth factor receptor signaling pathway; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of protein ubiquitination; negative regulation of smoothened signaling pathway; cartilage development; negative regulation of mitosis; negative regulation of astrocyte differentiation; lens morphogenesis in camera-type eye; positive regulation of endothelial cell proliferation; positive regulation of cell differentiation; phosphorylation; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.